Naomi B. Zak, PhD.
Dr. Sailaja Puttagunta M.D.
Dr. Sailaja Puttagunta, M.D., was most recently Vice President, Development at Iterum Therapeutics, a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens. Prior to Iterum, Dr. Puttagunta served as VP, Medical Affairs for Anti-infectives at Allergan from early 2015 and was the VP of Development and Medical Affairs at Durata Therapeutics, Inc. prior to its acquisition by Actavis plc. From 2006 to 2012, Dr. Puttagunta led teams within clinical development and medical affairs on various antibiotic compounds at Pfizer Inc. Dr. Puttagunta has 20 years of clinical, academic and research experience in medicine and in the sub-specialty of infectious diseases. She graduated from Gandhi Medical College in Hyderabad, India and completed her residency in Internal Medicine and a fellowship in Infectious Diseases at Yale University School of Medicine. She also holds an MS in Biochemistry from the New York University School of Medicine.
Rob Woodman, Ph.D
Dr. Rob Woodman joined TVI in March 2018 as Senior Partner, and is based in London, UK. Prior to joining TVI, Rob was Director of Healthcare Investments at Touchstone Innovations (formerly Imperial Innovations) in London. He has led the formation of and fundraising for a number of UK biotech companies, such as Mission Therapeutics, Crescendo Biologics, Storm Therapeutics, and Enterprise Therapeutics. Rob joined Touchstone Innovations in 2012 and was previously a Principal in the life science team at Sofinnova Partners, a leading European venture capital firm. While at Sofinnova, Rob was actively involved in numerous investments throughout Europe. Rob’s experience also includes technology transfer with Cancer Research Technology (CRUK) and pharmaceutical consultancy with IMS Health. Rob holds an MSc in Biochemistry from the University of Oxford and a Ph.D. in Oncology from the University of Cambridge.
Yaron Breski is a Founding Partner at RMGP Biopharma Investment Fund and Managing Director at RM Global. Mr. Breski holds over 14 years of experience in healthcare, finance, and business development, and is focused on developing and executing novel models to financing life science innovation. Previously, Mr. Breski served as a senior executive of business development at Rosetta Genomics, a biotech company focusing on cancer diagnostics. Before that Mr. Breski was part of the US Strategic Planning group at Novartis, and before with Booz Allen’s Healthcare group in New York. Mr. Breski holds a B.Sc. in Biology, Magna Cum Laude, research track for honors students from the Tel Aviv University; and an M.B.A from The Wharton School, University of Pennsylvania.
Prof. Rotem Sorek
and also develops techniques for high resolution understanding of microbial transcriptomics and metatranscriptomics. Prof. Sorek holds a Ph.D. in Human Genomics from Tel Aviv University, and in his postdoc, studied microbial metagenomics at the Lawrence Berkeley National Laboratory. Prior to joining the Weizmann Institute, Prof. Sorek headed the Genomics Research Group at Compugen (Nasdaq:CGEN). Prof. Sorek is also an author of numerous scientific publications in top-tier journals, and an inventor of more than 35 patents. He has received multiple awards, including the 2012 Rubinowitz-Grossman Prize in Microbiology, the 2013 Teva Founders Award for young scientists, and the 2014 FEBS Anniversary Prize. In 2015, Prof. Sorek was elected as a member of the European Academy of Microbiology.
Prof. Eran Elinav
Prof. Timothy K. Lu
Prof. Richard A. Flavell, Ph.D
Michael Koeris, Ph.D